iBio Explains Recent Filing of Registration Statement
02 Ottobre 2023 - 12:45PM
In response to investor inquiries received about the post-effective
amendment to its Form S-3 on Form S-1 (the “Post-Effective
Amendment”) filed on Friday, September 29, 2023 with the United
States Securities and Exchange Commission (“SEC”), iBio Inc.
(NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of
precision antibody immunotherapies, today provided the following
clarification.
The Company filed a registration statement on
Form S-3 (Registration No. 333-250973) (the “Original Registration
Statement”) declared effective by the SEC on December 7, 2020,
which registered up to $200,000,000 of any combination of iBio’s
common stock, preferred stock, debt securities, warrants or units
comprised of any of the foregoing securities of the Registrant.
This Post-Effective Amendment was filed to convert the Original
Registration Statement into a registration statement on Form S-1 in
order to maintain the registration of certain common stock warrants
issued and outstanding in connection with the Company’s December
2022 underwritten public offering, previously registered on the
Original Registration Statement.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About iBio, Inc.
iBio develops next-generation biopharmaceuticals
using computational biology and 3D-modeling of subdominant and
conformational epitopes, prospectively enabling the discovery of
new antibody treatments for hard-to-target cancers and other
diseases. iBio’s mission is to decrease drug failures, shorten drug
development timelines, and open up new frontiers against the most
promising targets. For more information, visit www.ibioinc.com.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release
constitute "forward-looking statements" within the meaning of the
federal securities laws. Words such as "may," "might," "will,"
"should," "believe," "expect," "anticipate," "estimate,"
"continue," "predict," "forecast," "project," "plan," "intend" or
similar expressions, or statements regarding intent, belief, or
current expectations, are forward-looking statements. These
forward-looking statements are based upon current estimates and
assumptions and include statements regarding filing the
registration statement on Form S-1 to maintain the registration of
certain common stock warrants issued and outstanding in connection
with the Company’s December 2022 underwritten public offering
previously registered on the Original Registration Statement. While
the Company believes these forward-looking statements are
reasonable, undue reliance should not be placed on any such
forward-looking statements, which are based on information
available to us on the date of this release. These forward-looking
statements are subject to various risks and uncertainties, many of
which are difficult to predict that could cause actual results to
differ materially from current expectations and assumptions from
those set forth or implied by any forward-looking statements.
Important factors that could cause actual results to differ
materially from current expectations include, among others, the
registration statement becoming effective; competition; the
Company’s ability to retain its key employees or maintain its NYSE
American listing; and the other factors discussed in the Company’s
filings with the SEC including the Company’s Annual Report on Form
10-K for the year ended June 30, 2023, and the Company’s subsequent
filings with the SEC on Forms 10-Q and 8-K. The information in this
release is provided only as of the date of this release, and the
Company undertakes no obligation to update any forward-looking
statements contained in this release on account of new information,
future events, or otherwise, except as required by law.
Contact:
Stephen KilmeriBio, Inc.Investor Relations(646)
274-3580skilmer@ibioinc.com
Grafico Azioni iBio (AMEX:IBIO)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni iBio (AMEX:IBIO)
Storico
Da Mag 2023 a Mag 2024